Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts

Benjamin P. Sharpe(University Hospital Southampton NHS Foundation Trust), Tim Underwood(University of Southampton)

Cell Reports Medicine

June 1, 2022

10.1016/j.xcrm.2022.100541

Cited by 24

Related Papers

Cancer‐associated fibroblasts predict poor outcome and promote periostin‐dependent invasion in oesophageal adenocarcinoma

|The Journal of Pathology|2014|182

Patient-derived tumor organoid and fibroblast assembloid models for interrogation of the tumor microenvironment in esophageal adenocarcinoma

|Cell Reports Methods|2024|10

Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma

|bioRxiv (Cold Spring Harbor Laboratory)|2020|2

Targetable fibroblast phenotypes and EMT malignant cell states cooperate to promote tumor progression in esophageal adenocarcinoma

|Research Square|2023|2